Inovalon on Thursday announced an agreement with Daiichi Sankyo, Inc., to support outcomes-based contracts and analyze abuse-deterrent opioids.
“Daiichi Sankyo is committed to responsibly bringing innovative medicines to patients in pain, and we believe abuse-deterrent formulations are an important part of a comprehensive approach to addressing the inappropriate use of opioid medications,” Daiichi Sankyo Administrative and Commercial President Ken Keller said in a statement.
